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In Vivo Occupancy of the k Light Chain Enhancers
in Primary Pro- and Pre-B Cells:
A Model for k Locus Activation
A. L. Shaffer, Albert Peng, and Mark S. Schlissel intronic enhancer in transgenic mice, by insertion of a
neomycin resistance gene or by loxP-mediated deletion,Department of Medicine
greatly diminishes k gene transcription and rearrange-Department of Molecular Biology and Genetics
ment (Takeda et al., 1993; Xu et al., 1996; Zou et al.,Graduate Program in Immunology
1993). The 39k enhancer, located about 9 kb downstreamThe Johns Hopkins University School of Medicine
of the Ck exon, also influences k gene transcription andBaltimore, Maryland 21205
rearrangement (Figure 1A; Blasquez et al., 1993; Meyer
and Neuberger, 1989; Meyer et al., 1990). Targeted dis-
ruption of the 39 enhancer also results in a significantSummary
decrease in k rearrangement and k locus transcription
(Gorman et al., 1996). In transgenic mice, reporter con-The immunoglobulin k light chain locus has two en-
structs containing only Vk, Jk, the intronic enhancer,hancer elements: the intronic enhancer, which lies be-
and Ck segments exhibit dysregulated V-to-Jk re-tween the Jk cluster and the Ck exon, and the 39k
arrangement; k light chain genes rearrange in T cellsenhancer, which is located downstream of Ck. To ad-
and at an increased level in pro-B cells (Goodhardt et al.,dress the contribution of these elements to the devel-
1989; Hiramatsu et al., 1995). Rearrangement reporteropmentally regulated activation of germline k locus
transgenes containing both the intronic and 39 en-transcription and rearrangement, we purified primary
hancers rearrange with appropriate lineage and stagepro- and pre-B cells and determined by in vivo foot-
specificity (Hiramatsu et al., 1995).printing thesites within each enhancer thatwere occu-
A multitude of transcription factor–binding sites havepied. We found that the k intronic enhancer NF-kB site
been characterized in each k enhancer, largely throughis occupied in both pro- and pre-B cells, while CRE,
the use of gel mobility shift and reporter construct trans-BSAP, and PU.1/pip sites within the 39k enhancer un-
fection assays (Figure 1A; reviewed by Staudt and Len-dergo changes in occupancy as cells progress from
ardo, 1991). The kB site in the intronic enhancer canthe pro-B to the pre-B cell stage. These findings sug-
bind a family of factors collectively called NF-kB. NF-gest that regulation of the k locus in primary pre-B
kB consists of homodimers and heterodimers of mem-cells may be mediated by factors that bind the 39k
bers of the rel family of transcription factors (reviewedenhancer.
by Grilli et al., 1993). NF-kB is found in the cytoplasm
of pre-B and non-B cell lines as an inactive complex
Introduction associated with an inhibitor, IkB. Its DNA binding activity
and nuclear relocalization can be activated via a post-
Immunoglobulin gene transcription and rearrangement translational mechanism by a variety of stimuli in trans-
are coordinately regulated during B cell development formed pre-B and nonlymphoid cell lines (Baeuerle and
(reviewed by Schatz et al., 1992). The appearance of Baltimore, 1988; Lenardo et al., 1987; Nelson et al., 1984;
transcripts from unrearranged immunoglobulin gene Sen and Baltimore, 1986a, 1986b). In mature primary as
segments (germline transcripts) correlates with the ac- well as transformed B cells, NF-kB is constitutively ac-
cessibility of particular immunoglobulin gene segments tive and localized in the nucleus (reviewed by Liou and
to the V(D)J recombinase both in vivo (reviewed by Baltimore, 1993).
Sleckman et al., 1996) and in vitro (Stanhope-Baker et NF-kB is an attractive candidate for controlling k locus
al., 1996). During B cell development, heavy chain gene activation during B cell development since treatment of
rearrangement usually precedes light chain gene re- transformed pre-B cells with bacterial lipopolysaccha-
arrangement. Successful heavy chain gene rearrange- ride (LPS) activates NF-kB and is associated with in-
ment leads to the expression of immunoglobulin m (Igm) creased germline k transcription and V-to-Jk rearrange-
protein in pre-B cells and is associated with increased ment (Atchison and Perry, 1987; Lenardo et al., 1987;
germline k gene transcription and V-to-Jk rearrange- Schlissel and Baltimore, 1989). In addition, in a condi-
ment (Li et al., 1993; Schlissel and Morrow, 1994; Spano- tionally transformed pro-B cell line, NF-kB is dere-
poulou et al., 1994; Van Ness et al., 1981; Young et al., pressed by growth at the restrictive temperature coordi-
1994). The mechanism by which m protein expression nate with activation of germline k gene transcription
in developing pre-B cellsactivates germline k locustran- and rearrangement (Chen et al., 1994; Klug et al., 1994).
scription and rearrangement is not understood. Finally, there is evidence from in vivo footprinting of
Two tissue-specific enhancers are associated with the intronic enhancer in a transformed cell line that
the control of transcription and rearrangement of the k the NF-kB site (as well as an E-box site) is occupied
locus (Figure 1A). The intronic enhancer is located in only in cells with active k genes (Hromas et al., 1988).
the intron between the Jk cluster and the k constant Together, these data lead to the hypothesis that devel-
region exon, Ck (Figure 1; Emorine et al., 1983; Parslow opmentally regulated activation of NF-kB in pre-B cells
and Granner, 1982; Picard and Schaffner, 1986; Queen results in its binding to the k intronic enhancer, the
and Baltimore, 1983). In some reporter construct re- induction of germline k transcription, and V-to-Jk gene
arrangement assays, the presence of the k intronic en- rearrangement.
hancer increases the efficiency of gene rearrangement Results of experiments involving the targeted disrup-
tion of various individual rel family members, however,(Oltz et al., 1993). In addition, targeted disruption of the
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Figure 1. The Effect of LPS Treatment on the
In Vivo DMS Footprint of the Igk Intronic En-
hancer
(A) Map of the murine k light chain locus and
the k enhancers. An approximately 15 kb
EcoRI fragment contains the Jk and Ck re-
gions (open boxes) of the murine k locus, as
well as the k intronic enhancer (Eki) and the
39k enhancer (Ek39). Expanded views of the
two enhancers show the relative positions of
potential factor-binding sites identified by in
vitro binding assays and transfected reporter
construct experiments (Cockerill and Gar-
rard, 1986; Costa and Atchison, 1996; Meyer
and Ireland, 1994; Roque et al., 1996;
Schanke et al., 1994; Staudt and Lenardo,
1991).
(B) In vivo DMS footprinting of the k intronic
enhancer in transformed pro-B and pro-T cell
lines. A section of an autoradiogram dis-
playing the LM–PCR in vivo DMS footprint of
the intronic enhancer in 220-8 pro-B cells and
2017 pre-T cells cultured in the presence and
absence of either LPS or PMA is shown. Posi-
tions were assigned to the G ladder using an
appropriate set of DNA sequencing reactions
electrophoresed on the same denaturing
polyacrylamide gel (data not shown). The
numbers indicate nucleotide positions on the
published murine k locus DNA sequence
(Max et al., 1981). Factor-binding sites are
diagrammed to the left of the footprint. Each
band represents a G residue on the upper
strand of the DNA. Lane 1 shows the pattern
of G residues obtained from purified genomic
DNA treated with DMS in vitro, with four con-
tiguous G residues evident at the 59 end of the
NF-kB site. The invivo DMS footprint patterns
from unstimulated 220-8 cells (lane 2), LPS-
stimulated 220-8 cells (lane 3), unstimulated
2017 pre-T cells (lane 4), and PMA-treated
2017 cells (lane 5) are shown. LPS-induced
hypersensitivity at the NF-kB site is noted by
an arrow, and protection of the kE2 site is
indicated by a closed oval.
have cast doubt on the role of NF-kB in the activation activities, is thought to be involved in the regulation of
several different pre-B and mature B cell–specific genesof k locus transcription and rearrangement. Disruption
of rel family members p50, c-rel, and RelB does not (Busslinger and Urbanek, 1995). Targeted mutation of
BSAP results in the arrest of B cell development prioraffect k locus activation as assessed by Igk expression
on the surface of mature B cells in mutant animals (Kont- to the onset of immunoglobulin gene rearrangement (Ur-
banek et al., 1994), and PU.1 disruption results in abla-gen et al., 1995; Sha et al., 1995; Weih et al., 1995). The
effects of p65 (RelA) disruption could not be analyzed tion of both myeloid and lymphoid precursors (Scott et
al., 1994). The nature of these null phenotypes precludesin this fashion, since the mutant animals die during mid-
gestation (Beg et al., 1995). In addition, it remains possi- analysis of the roles of these factors ink locus activation.
To determine the precise role of each k enhancer inble that various rel family members can substitute for
one another, obscuring the critical role of any individual activating the k locus during early B cell development,
we employed a transgenic mouse model that allows usfactor.
Several recent studies have led to the suggestion that to analyze populations of primary cells arrested at the
pro- and pre-B cell stages of development. A combina-the less well-studied 39k enhancer may play an impor-
tant role in developmental regulation of the k locus (Gor- tion of in vivo footprinting and gel mobility shift analyses
revealed differences in the way germline k transcriptionman et al., 1996; Hiramatsu et al., 1995; Roque et al.,
1996). This enhancer contains binding sites for a B cell– is activated in primary cells compared with transformed
cell lines. In addition, we were able to identify enhancer-restricted transcription factor BSAP (also known as
Pax-5; Roque et al., 1996) and an ets family factor PU.1 binding sites and factors in primary cells that might
interact to activate germline k transcription and re-(Pongubala et al., 1992). These factors are both ex-
pressed in immature and mature B cells. BSAP, which arrangement during the pro- to pre-B cell transition in
vivo.can have both transcription enhancing and silencing
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Results These in vivo footprint results lend strength to the
idea that LPS induction of NF-kB binding activity in
transformed pro-B cell lines results in intronic enhancerFactors Involved in the Activation of the k
Locus in Transformed Pro-B Cell Lines occupancy and k locus activation (Hromas et al., 1988)
and point to a critical role for NF-kB- and E-box-bindingAs discussed above, there is a body of correlative data
suggesting that LPS induction of NF-kB binding activity proteins in k locus activation. However, the binding of
NF-kB to its site in the intronic enhancer must dependmight be responsible for the activation of the k locus in
pro-B cell lines (Grilli et al., 1993; Hromas et al., 1988; at least in part on other chromosomal proteins, since
nuclear NF-kB does not occupy its binding site in pre-Schlissel and Baltimore, 1989; Sen and Baltimore,
1986a, 1986b). This cell line phenomenon has been used T (Figure 1B, lanes 4 and 5) and several nonlymphoid
cell lines (data not shown; reviewed by Grilli et al., 1993).as a model for the developmental regulation of k locus
activation. Figure 1A shows a diagram of the k locus
indicating the positions of each enhancer and a subset Occupancy of the k Intronic Enhancer
across the Pro- to Pre-B Cellof their potential factor-binding sites (Staudt and Len-
ardo, 1991). To test the hypothesis that activation of the Transition In Vivo
Developing B cells show coordinate activation of germ-k locus is a result of transcription factor binding to the
intronic enhancer NF-kB site, we treated the Abelson line k locus transcription and rearrangement at the pre-
B cell stage (Young et al., 1994; Schlissel and Morrow,murine leukemia virus–transformed pro-B cell line 220-
8 with LPS for 18–24 hr, conditions previously shown to 1994; Spanopoulou et al., 1994). To determine whether
NF-kB induction during the pro- to pre-B cell transitionactivate NF-kB binding as well as germline k transcrip-
tion and gene rearrangement (Schlissel and Baltimore, in vivo results in intronic enhancer occupancy and regu-
lated activation of the k locus as it does in LPS-treated1989; Sen and Baltimore, 1986b). In addition, we treated
the pre-T cell line 2017 with phorbol myristate acetate pro-B cell lines, we analyzed two strains of transgenic
mice whose B cells are arrested at specific points in B(PMA) for 4 hr, which has been previously shown to
activate NF-kB in T cells (Sen and Baltimore, 1986a). cell development (Figure 2A). Mice with a disruption of
the RAG1 gene (RAG2/2) are incapable of initiating geneGel mobility shift analyses confirmed that the treatments
induced similar levels of NF-kB DNA binding activity rearrangement and are arrested atthe pro-B cell stage of
development before activation of the k locus. Breeding(data not shown). The various cell cultures were har-
vested by centrifugation, treated with the membrane- these mice to mice that express a functionally re-
arranged heavy chain transgene allows developing Bpermeable DNA-methylating agent dimethyl sulfate
(DMS), and subjected to in vivo footprint analysis using a cells to assemble a pre-B cell receptor (pre-BCR) and
progress to the pre-B cell stage, where they activateligation-mediated polymerase chain reaction approach
(LM–PCR; Mueller and Wold, 1989; Figure 1B). Treat- germline k gene transcription (RAG2/2, m heavy chain
transgenic mice; Figure 2A; Spanopoulou et al., 1994;ment of purified genomic DNA with DMS in vitro revealed
the complete pattern of G residues across a 97 nt region Young et al., 1994). Bone marrow B cell precursors were
isolated from groups of mice of each genotype by posi-of the top strand of the k intronic enhancer (Figure 1B,
lane 1). We noted little difference between this pattern tive selection for the expression of the pan–B cell marker
CD19. A representative example of such a purification isand the in vivo pattern from 220-8 cells cultured in the
absence of LPS (Figure 1B, lane 2). LPS treatment of shown in Figure 2B. Cell fractions designated “enriched”
were greater than 90% CD191. Those fractions called220-8 cells, however, led to the appearance of two foot-
prints. First, we detected striking hypersensitivity to “depleted” are non-B cells and contain less than 10%
CD191 cell contamination. All subsequent analyses ofDMS modification at a cluster of four consecutive G
residues in the NF-kB site (Figure 1B, compare lanes 2 primary cells used materials derived in this manner.
Figure 3 shows the DMS in vivo footprint of the kand 3, closed arrow), indicating occupancy of the NF-
kB site in these cells. In addition, we observed induction intronic enhancer in purified, primary pro- and pre-B
cells. Non-B cells, the depleted fractions, show a patternof a protected region over the kE2 E-box site (compare
lanes 2 and 3, closed oval). We observed similar LPS- of G residues identical to the pattern generated by in
vitro DMS treatment of purified DNA (Figure 3, compareinducible NF-kB and kE2 footprints in a wide array of
transformed pro-B cell lines (data not shown). The 2017 lane 1 with lanes 2 and 5). RAG2/2, m transgenic pre-B
cells show a footprint at the 59 end of the NF-kB-bindingtransformed T cell line (Spolski et al., 1988) showed
no occupancy of the NF-kB or E-box sites even after site (Figure 3, lane 4), similar to that seen in LPS-stimu-
lated B cell lines (Figure 1B). RAG2/2 pro-B cells, how-treatment with PMA (Figure 1B, lane 5). Similarly, we
failed to detect any intronic enhancer footprint in freshly ever, also have a dramatic hypersensitive site (Figure 3,
lane 3), identical to the one observed in pre-B cells,prepared thymocytes, despite their well-documented
expression of NF-kB (data not shown; Zuniga-Pflucker despite the fact that these cells do not appreciably tran-
scribe their k loci (data not shown; Spanopoulou et al.,et al., 1993). Using this approach, we failed to observe
occupancy of other sites on this strand or the opposite 1994; Young et al., 1994). In contrast with our observa-
tions on LPS-treated pre-B cell lines, we saw no signifi-strand in any B lineage cell line (between the matrix
attachment region [MAR] and kE3 box in Figure 1A; data cant footprint over the kE2 box in either the pro- or pre-B
cell stages of development. Once again, footprinting onnot shown). In vivo footprint analysis of the 39k enhancer
in a panel of transformed cell lines failed to reveal any the opposite strand showed no differences between
primary RAG2/2 and RAG2/2, m transgenic B cell popula-binding sites whose occupancy changed with LPS treat-
ment (data not shown; see below). tions, and no other sites between the 59 MAR element
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Figure 2. The Purification of Primary Pro- and Pre-B Cells from Mu-
tant Bone Marrow
(A) Transgenic system for obtaining pure pro- and pre-B cells.
Shown in schematic form is the progression of cells through the B
lineage. Pro-B cells do not express immunoglobulin heavy chain
protein. Pre-B cells assemble a complete immunoglobulin heavy
chain (Hc) with proteins called surrogate light chains (SLCs) into a
complex called the pre-BCR. Cells ultimately rearrange and express
a light chain (Lc) to become IgM-positive B cells. B cells from RAG1-
deficient mice arrest at the pro-B cell stage (RAG2/2), while cells
from RAG1-deficient, m heavy chain transgenic mice (RAG2/2, m)
progress to the pre-B cell stage, but arrest before the B-cell stage.
(B) Purification of primary pro-B cells from RAG2/2 bone marrow.
Figure 3. In Vivo DMS Footprint Analysis of the k Intronic Enhancer
Analysis of a representative primary cell (RAG2/2, pro-B) purification
in Primary Pro- and Pre-B Cells
is shown. Unfractionated bone marrow B cells from several mice
The indicated populations of primary cells were purified as de-were pooled and stained with an antibody to the pan B cell marker
scribed in Figure 2 and treated with DMS. In addition, purified geno-CD19 (21% of nucleated bone marrow cells). After positive selection
mic DNA was treated in vitro with DMS. Both types of DNA wereof cells using biotinylated anti-CD19 antibodies and streptavidin
analyzed by LM–PCR footprinting with primers specific for the upperparamagnetic beads, fractions were reanalyzed for CD19 staining.
strand of Eki. An autoradiogram of a denaturing polyacrylamide gelThe depleted population consists of non-B cells that contain fewer
is shown. The same region of Eki is shown as in Figure 1B, with thethan 10% CD191 cells. Enriched populations were always .90%
positions of transcription factor–binding sites indicated to the leftCD191 B cell precursors. The identity of the cells as B cell precursors
(open boxes). The in vitro DMS-treated control (lane 1) reveals thewas simultaneously confirmed by flow cytometric analysis of stain-
pattern of G residues at this locus. Lanes 2 and 5 show the footprintsing for the B cell marker B220 and by forward and side scatter
from non-B cells isolated as the depleted fractions after positivecriteria (data not shown). The decrease in intensity of CD19 staining
selection. The central lanes (3 and 4) show the footprints of primaryseen in the enriched fraction is due to interference of the paramag-
pro- and pre-B cells. The arrow indicates a DMS hypersensitivenetic beads with secondary reagents used to detect CD19.
site at the 59 G residues of the NF-kB site similar to that seen in
transformed cell lines (Figure 1B).
and the 39 kE3 box in the intronic enhancer showed a
footprint (data not shown).
The footprints observed in primary cells were unex- These dimers can have different effects on transcrip-
tional activation depending on both the proteins andpected based on the observations made with trans-
formed cell lines. It remained possible, however, that specific DNA sequence involved (Fujita et al., 1992).
To analyze the factors available for binding to thethe similar primary cell footprints might be the result of
different factors binding the intronic enhancer NF-kB intronic enhancer NF-kB site in pro- and pre-B cells, we
prepared nuclear extracts from purified primary cellssite at successive stages of development. NF-kB is a
dimer composed of members of rel family transcription and cell lines. These extracts contained similar amounts
of the ubiquitous Oct-1 transcription factor assayed byfactors that can homodimerize and heterodimerize.
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Figure 4. Gel Mobility Shift Analysis of rel
Family Transcription Factors in Primary Pro-
and Pre-B Cells
(A) Gel shift analysis of factors in nuclear ex-
tracts from pro- and pre-B cells that bind to
NF-kB or octamer probes. Nuclear extracts
from the indicated sources were incubated
with a radiolabeled probe containing either
the Eki NF-kB site (upper panel) or the oc-
tamer site (lower panel) from the immuno-
globulin heavy chain enhancer. An auto-
radiogram of the native polyacrylamide gel
analysis of DNA–protein complexes is shown.
Two specific NF-kB complexes considered
in the text are noted with arrows. The assays
in lanes 3 and 4 (top) contained specific (sp.)
and nonspecific (nonsp.) unlabeled oligonu-
cleotide competitor DNAs. Lanes 9 and 10
contain extracts of wild-type bone marrow
non-B cells and B cells purified using anti-
CD19, and lanes 11 and 12 contain extracts
of purified splenic B and T cells. The lower
panel is a mobility shift with an octamer pro-
tein-binding site, which confirms the integrity
and equivalence of each nuclear extract. The
upper complex is likely Oct-1 and the lower
Oct-2 (arrows).
(B) Gel mobility supershift analysis of primary
pro- and pre-B cell proteins binding to the
Eki NF-kB site. Gel shift binding reactions
were performed as in (A) with the addition of
nonspecific control antisera (NS) or antisera
specific for rel family transcription factors (in-
dicated above each lane). Nuclear extracts
were prepared from primary pro-B cells
(lanes 1–6), pre-Bcells (lanes 7–12), total wild-
type bone marrow (BM) B lymphocytes (lanes
13–18), and wild-type splenic (SPL) B cells
(lanes 19–24). Arrows indicate the two spe-
cific NF-kB complexes.
gel mobility shift of an octamer-containing oligonucleo- determine whether the composition of either the upper
complex or lower complex was different in pro- andtide probe (Figure 4A, bottom; Staudt et al., 1988), con-
firming their relative equivalence and integrity. Using an pre-B cells (Figure 4B). Nuclear extracts were preincu-
bated with antisera directed against individual rel familyintronic enhancer NF-kB site probe, we observed two
shifted complexes, a slow-migrating inducible complex members or with a nonspecific antisera prior to interac-
tion with the NF-kB site probe. We detected a similar setand a fast-migrating constitutive complex, in assays
using nuclear extracts from the RAG2-deficient pro-B of supershifted species at each stage of development,
although the relative amounts of specific complexescell line 63-12 cultured with and without LPS (Figure 4A,
lanes 1 and 2). Both complexes were specific for the differed between pro- and pre-B cells. The upper com-
plex in RAG2/2 pro-B cells contained predominantlyNF-kB site as demonstrated by competition with an ex-
cess of unlabeled NF-kB oligonucleotide as compared p50/p65 heterodimer (Figure 4B, lane 3), while that in
RAG2/2, m transgenic pre-B cells contained similarwith a nonspecific oligonucleotide (Figure 4A, lanes 3
and 4). The two specific complexes (arrows) were also amounts of p50/p65 and p50/c-rel (lanes 9 and 12). In
contrast, theupper complex in mature B cells (Figure 4B,evident in primary cells. We found that the upper com-
plex was enriched in all purified lymphocyte populations lanes 19–24) contained all assayed rel family members,
demonstrating the activity of each antisera. The lower(for example, compare lanes 9 and 10 in Figure 4A). The
amount of each complex and the relative ratio of the complex was only affected by anti-p50 antibodies, sug-
gesting that it might be a p50 homodimer. We concludeupper complex to the lower complex appeared equiva-
lent in primary pro- and pre-B cells (Figure 4A, lanes 6 from these experiments that, unlike transformed cell
lines, primary pro- and pre-B cells both contain similarand 8).
Gel mobility supershift analyses were performed to amounts of active NF-kB, but the various components
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Figure 5. In Vivo DMS Footprint Analysis of
the 39k Enhancer in Primary Pro- and Pre-B
Cells
(A) Top strand. Footprinting was performed
as described for the intronic enhancer (Fig-
ures 1 and 3) on pro- and pre-B cells purified
from RAG2/2 and RAG2/2, m transgenic bone
marrow. Previously described potential tran-
scription factor–binding sites are shown to
the left of the footprint. In vitro DMS-treated
DNA (lane 1) compared with an appropriate
DNA sequencing ladder (data not shown)
shows the pattern of G residues from posi-
tions 401–490 of the 39k enhancer (numbering
as in Meyer and Neuberger, 1989). “Enriched”
and “depleted” refer to cells purified based
on the expression of CD19 (Figure 2). Primary
pro- and pre-B cell footprints (lanes 3 and
4) are compared in histograms next to the
footprint, generated by phosphorimager
analysis of the primary data using Im-
ageQuant software. Several of the differ-
ences between the pro-B (solid line) and
pre-B (broken line) footprints are indicated
by arrows (hypersensitive sites) and open cir-
cles (protected sites). Transcription factor–
binding sites are diagrammed above the his-
tograms.
(B) Bottom strand. The same DNA samples
used in (A) were analyzed by LM–PCR for the
bottom strand footprint. Labels and histo-
grams are as in (A). The asterisk along the
footprint indicates a particular residue dis-
cussed in the text.
of this activity show quantitative variation, which might previously described cyclic AMP response element
(CRE) in pre- but not pro-B cells (Figure 5B, comparecontribute to differences in k locus transcription. It re-
mains uncertain, however, which of these NF-kB com- lanes 3 and 4; Pongubala and Atchison, 1995). Second,
we detected a change in the pattern of DMS reactivityplexes is responsible for the in vivo footprints we ob-
served in pro- and pre-B cells (see Figure 2). in the center of a BSAP-binding site (Roque et al., 1996)
when comparing lanes 3 and 4 in Figure 5B. A G residue,
indicated by the asterisk, is relatively protected in pro-BIn Vivo Analysis of the 39k Enhancer across
cells but reactive in pre-B cells and non-B cells. Finally,the Pro- to Pre-B Cell Transition
the most striking difference we observed was in theSince the intronic enhancer footprint did not show any
region of the PU.1/pip-binding site (Pongubala et al.,differences that could explain the developmental regula-
1992). We found a combination of protection and hyper-tion of the k locus, we turned to analysis of the 39k
sensitivity in pre-B cells at this site on the top strandenhancer, which lies approximately 9 kb downstream
(Figure 5A, lanes 3 and 4) and a correspondinghypersen-of the k constant region (see Figure 1A; Meyer and Neub-
sitive site in pre-B cell DNA on the bottom strand (Figureerger, 1989). In vivo footprint analysis was performed
5B, lanes 3 and 4). Graphical phosphorimage analyseson both strands of this enhancer as shown in Figure
demonstrated the extents of protection and hypersensi-5. Comparing the enriched primary RAG2/2 pro- and
tivity (Figure 5).RAG2/2, m transgenic pre-B cell populations (Figures 5A
The footprints described above and shown in Figure[upper strand] and 5B [lower strand], lanes 3 and 4) with
5 were reproducible using three different preparationseither the in vitro DMS-treated DNA control (lane 1) or
of RAG2/2 and RAG2/2, m transgenic pro- and pre-Bthe nonlymphocyte (depleted) samples (lanes 2 and 5),
cells. Despite the presence of other factor-binding siteswe detected three regions of developmentally regulated
in this region defined by a variety of in vitro assays, noprotection or hypersensitivity. First, we found a hyper-
sensitive site on the bottom strand of the 59 end of a other footprints were evident on either strand of the 39k
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Figure 6. Analysis of the Factors Binding the
39k Enhancer in Cell Lines and Primary Cells
(A) Mobility shift analysis using a BSAP–PU.1/
pip probe. Equivalent amounts of nuclear ex-
tracts prepared from anti-CD19 antibody–
purified primary pro- and pre-B cells (lanes 1
and 2), splenic B cells (lanes 3–14), and bone
marrow B cells (lane 15) and unfractionated
thymocytes (lane 16)were mixed with a radio-
labeled BSAP–PU.1/pip probe in the pres-
ence or absence of excess competitor oligo-
nucleotides or various antisera as indicated.
An autoradiogram of the native polyacryl-
amide gel analysis of DNA–protein com-
plexes is shown. A complex present in B cells
and identified as BSAP is indicated by the
closed arrow and a unique pro-B cell–derived
PU.1 site–specific complex is indicated by
the open arrow. Competitors include the fol-
lowing: OCT, octamer-binding site; m39B,
mutant 39k enhancer BSAP site; 39B, 39k
enhancer BSAP site; 19B, CD19 promoter
BSAP site; m39PU.1/pip, mutant 39k enhancer
PU.1 site; 39PU.1/pip, intact 39k enhancer
PU.1 site; and lBPU.1/pip, Igl enhancer PU.1
site. In lanes 12–14, splenic B cell nuclear
extract was preincubated with preimmune
serum or anti-PU.1 or anti-pip antisera prior
to analysis.
(B) Mobility shift analysis using mutant
probes. The same nuclear extracts from (A)
(as indicated by lane numbers) were analyzed
for binding to radiolabeled BSAP–mutant
PU.1/pip (left panel) and mutant BSAP–PU.1/
pip (right panel) oligonucleotides. Arrows are
as in (A).
(C) Mobility shift analysis of primary and cell line extracts using a minimal 39k enhancer BSAP site probe. A radiolabeled oligonucleotide
containing the 39k enhancer BSAP site was used to analyze nuclear extracts from RAG2/2-depleted, RAG2/2-enriched, RAG2/2, m transgenic–
enriched, and RAG2/2, m transgenic–depleted (lanes 17–20, respectively), two samples of thymus (lanes 21 and 22), and purified splenic B
and T cells (lanes 23 and 24). The arrow indicates the BSAP-specific complex as determined by competitor studies (data not shown). An
autoradiogram of the native polyacrylamide gel analysis of DNA–protein complexes is shown.
(D) Mobility shift analysis using an octamer probe. The same RAG2/2 pro-B (lane 1), RAG2/2, m transgenic pre-B (lane 2), splenic B (lane 3),
and thymocyte (lane 16) nuclear extracts used in (A)–(C) were analyzed for binding to a radiolabeled octamer-containing oligonucleotide. An
autoradiogram of the native polyacrylamide gel analysis of DNA–protein complexes is shown. The arrow indicates the position of the Oct-1
DNA–protein complex.
enhancer in primary pro- or pre-B cells (a region from sites gave essentially identical results and did not reveal
CRE- or E-box-specific complexes.nucleotide 253 to 690; Meyer and Neuberger, 1989; see
Experimental Procedures; data not shown). We identified the slow-migrating complex (Figure 6A,
closed arrow), evident in all the B lineage extracts, as
BSAP based on its pattern of competition (lanes 3–10)Factors Binding the 39k Enhancer
in Primary Pro- and Pre-B Cells with oligonucleotides containing the previously charac-
terized BSAP sites from the 39k enhancer and the CD19Our in vivo footprinting analysis revealed developmen-
tally regulated changes in factor binding to the BSAP– promoter (Roque et al., 1996; Zwollo and Desiderio,
1994). This complex could not be competed by a mutantPU.1 region of the 39k enhancer. BSAP and ets family
factors (such as PU.1) have been shown recently to BSAP oligonucleotide or by octamer or PU.1 site oligo-
nucleotides. We reproducibly found less of this BSAPinteract when bound to adjacent sites in various B cell–
specific promoter and enhancer sequences (Fitzsim- complex in primary pre-B cells than in pro-B cells (Fig-
ures 6A and 6B, lanes 1 and 2). We confirmed this obser-mons et al., 1996; Neurath et al., 1994, 1995; Singh and
Birshtein, 1993). In an attempt to determine which fac- vation using a labeled oligonucleotide containing only
the 39k enhancer BSAP site (Figure 6C, lanes 18 andtors might be responsible for changes in our in vivo
footprints, we analyzed enhancer-binding factors in nu- 19). To assess the comparability of our pro- and pre-B
cell nuclear extracts, we analyzed their binding to anclear extracts by gel mobility shift assay. Using an oligo-
nucleotide probe encompassing the BSAP to PU.1/pip octamer-containing oligonucleotide and found that
these extracts contained similar amounts of the ubiqui-region of the enhancer, we detected a series of DNA–
protein complexes in nuclear extracts from primary tous Oct-1 transcription factor (Staudt et al., 1988), con-
firming their relative equivalence and integrity (Fig-pro-B, pre-B, mature B, and progenitor T cells (Figure
6A). Larger probes that included the CRE and E-box ure 6D).
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Interestingly, we detected a complex of mobility simi- transformed cells as a model system, however. Pro-B
cells transformed with a temperature-sensitive mutantlar to the B cell BSAP complex in thymocyte nuclear
Abelson virus were shown to repress NF-kB activityextract (Figure 6A, lane 16). A thymocyte complex of
under culture conditions that maintained the activity ofidentical intensity still formed on an otherwise identical
the v-abl kinase (Klug et al., 1994). When kinase activityprobe containing a mutant BSAP site (Figure 6B, right,
was eliminated by shift to the nonpermissive tempera-lane 16) and was not competed by an unlabeled BSAP
ture, NF-kB was activated along with germline k tran-oligonucleotide (data not shown). This complex did not
scription and V-to-Jk gene rearrangement (Chen et al.,form efficiently on the smaller BSAP site probe (Figure
1994). This led to the suggestion that abl-transformed6C, lanes 21 and 22). The intensity of this thymocyte
cell lines are interrupted in the execution of their devel-complex increased, however, when a BSAP–PU.1 probe
opmental program by oncogenic transformation, lead-with a mutant PU.1 site was used (Figure 6B, left, lane
ing to a misinterpretation of the role of NF-kB and the16). The behavior of this T cell complex raises the possi-
intronic enhancer in the activation of the k locus.bility of its involvement in the regulation of the k locus
More recent approaches to the problem of Igk locusin thymocytes (Hiramatsu et al., 1995; see below).
regulation have taken advantage of transgenic and tar-We identified a second B cell–restricted DNA–protein
geted mutant mice. These studies have shown that bothcomplex as PU.1 (Figures 6A and 6B, open arrow). In
k enhancers are required for transcription and properlysplenic B cell extract, this complex could be competed
restricted rearrangement of the k locus (Blasquez etspecifically with an oligonucleotide containing the PU.1
al., 1993; Goodhardt et al., 1989; Gorman et al., 1996;site from either the 39k enhancer or the Igl enhancer
Hiramatsu et al., 1995; Takeda et al., 1993; Xu et al.,(Figure 6A, lanes 9 and 10; Eisenbeis et al., 1993; Pongu-
1996; Zou et al., 1993). This approach has identifiedbala et al., 1992), but not with a series of other competi-
broad regions of DNA that are involved in the regulationtors (Figure 6A, lanes 3–10). In addition, formation of
of the k locus, but not the specific factor-binding sitesthis complex was ablated by treatment of splenic B
that are important in vivo. Conversely, targeted disrup-cell nuclear extract with anti-PU.1, but not anti-pip or
tion of specific transcription factors (reviewed by Desid-preimmune antisera (lanes 11–14). We observed that the
erio, 1996) has not directly identified those important toPU.1 complex was present in primary pre-B cell but not
k locus activation at the pre-B cell stage. The disruption
pro-B cell nuclear extract (Figure 6A, lanes 1 and 2). A
of relevant transcription factors in mice has thus far
PU.1 complex was detected in pro-B cells, however,
resulted in two general phenotypes. First, several
when a mutant BSAP site–containing probe was used
groups have observed embryonic lethality or ablation
(Figure 6B, right, lane 1), suggesting that BSAP binding
of the B cell lineage before the developmental stage of
inhibits PU.1 binding to the enhancer. This antagonism
interest (Bain et al., 1994; Scott et al., 1994; Urbanek et
between BSAP and PU.1 may explain some of the al., 1994; Zhuang et al., 1994). This is not surprising
changes in the in vivo footprint we observed between since this approach only reveals the first point at which
pro- and pre-B cells (see below). a factor is required. Second, other targeted mutations
showed normal k expression. If one targets a member
of a large family of factors, loss of one factor may be
Discussion
compensated for at a particular stage by another family
member, resulting in no phenotype at the stage of inter-
The regulation of Igk locus transcription and re- est. This might be responsible for the failure to observe
arrangement has been intensively studied during the an effect of rel family member mutation on Igk locus
past decade. Transcriptional enhancers associated with activation (Kontgen et al., 1995; Sha et al., 1995; Weih
the k locus were identified by transfection of reporter et al., 1995).
constructs into transformed cell lines, and protein-bind- We have pursued an alternative approach to elucidate
ing sites within these enhancers were identified and the roles of the intronic and 39k enhancers in the devel-
studied byvarious in vitro binding assays and mutational opmental regulation of the k locus. We analyzed the
analyses. Subsequently, the potentially relevant DNA- roles of specific DNA-binding sites through in vivo DMS
binding proteins were purified and characterized and footprint analysis of both k enhancers in highly purified
their genes were cloned based on their in vitro binding primary pro- and pre-B cells. These studies allowed
activity. These initial studies led to hypotheses regard- us to identify which factor-binding sites were actually
ing the roles of specific DNA sequences and transcrip- occupied in vivo and, of those, which sites changed
tion factors in the developmental regulation of Igk locus occupancy in concert with developmentally regulated
expression. These approaches could not, however, de- transcriptional activation. Finally, we used nuclear ex-
termine which of the many transcription factors and their tracts from these purified primary cells to identify spe-
binding sites were critical for regulated expression of cific DNA-binding proteins capable of binding relevant
the Igk locus at various stages of B cell development sites in vitro.
in vivo.
LPS-treated Abelson virus–transformed pro-B cell Differences between the Transcription Factors
lines have been used as a model of the pro- to pre-B Involved in the Activation of the Igk Locus
cell transition. As noted above, LPS treatment of these in Transformed and Primary Pre-B Cells
cells induces correlated increases in NF-kB DNA binding In transformed pro-B cell lines, we found that occupancy
activity, germline k gene transcription, and V-to-Jk gene of the intronic enhancer NF-kB site was strictly corre-
rearrangement (Schlissel and Baltimore, 1989). Recent lated with germline k locus transcription (Figure 1). Cul-
tured pro-B cell lines expressed little or no germline kstudies have cast doubt on the validity of Abelson virus–
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transcript (Nelson et al., 1985; Parslow and Granner, involved previously characterized binding sites for
BSAP and PU.1, in addition to a less well-studied CRE-1982; Schlissel and Baltimore, 1989) and lacked the NF-
kB site footprint (Figure 1). When the cells were cultured binding protein. Pro-B cells showed a protected nucleo-
tide in the BSAP site, while pre-B cells showed bothwith LPS, we observed the coincident increase of germ-
line k transcription (Nelson et al., 1985; Schlissel and protection and hypersensitivity within the PU.1/pip site
and hypersensitivity of a nucleotide flanking the CREBaltimore, 1989) and the in vivo NF-kB site footprint
(Figure 1), confirming previous observations made by site. These footprints are qualitatively similar to those
observed by Roque et al. (1996). These workers, how-others (Hromas et al., 1988). In addition, with LPS treat-
ment a footprint appeared over the kE2 element in the ever, observed BSAP and PU.1 footprints in both pro-
and pre-B cell lines. In contrast, we observed distinctintronic enhancer (Figure 1). We failed to detect foot-
prints in other previously described binding sites in ei- footprints at the pro- and pre-B cell stages: a BSAP
region footprint in primary pro-B cells and a CRE/PU.1ther the intronic or 39k enhancers in these transformed
cells (Figure 1; data not shown). Therefore, we propose footprint in primary pre-B cells. As was the case for the
NF-kB site in the k intronic enhancer, cell line experi-that in transformed cell lines, the k locus is activated
by NF-kB or E-box proteins binding to their sites in the ments were critical for the identification of the relevant
factors and their binding sites, but the behavior of theseintronic enhancer. It remains possible that other tran-
scription factors bind to the k enhancers in transformed factors in cell lines did not accurately reflect the in vivo
regulation of factor binding to the 39k enhancer.cells, since DMS has obvious limitations as a foot-
printing probe owing to its small size and its reactivity Gel mobility shift analyses of nuclear extracts from
the same primary cells revealed decreased BSAP andbeing limited to G (and sometimes A) residues in DNA.
Further studies using other footprinting agents will be increased PU.1 binding activity across the pro- to pre-B
cell transition (Figure 6). When assayed with a mutantnecessary to search for other relevant factor-binding
sequences. The activation of NF-kB alone, however, BSAP site–containing probe, the levels of the PU.1 com-
plex in pro-B cells increased, leading us to suggest thatdoes not result in its binding to the intronic enhancer in
a pre-T cell line (Figure 1). This result leads us to sug- BSAP binding might inhibit PU.1 binding. Employing a
probe containing only the BSAP site, we observed thatgest that other transcription factors must be required
to allow access of NF-kB to its binding site in B cells binding decreased as cells moved from the pro- to pre-B
cell stage (Figure 6C), while mobility shift analysis usingor to prevent access in T cells (Pierce et al., 1991).
To our surprise, we found that the NF-kB site was a PU.1/pip site probe revealed equivalent binding activ-
ity in both pro- and pre-B cells (data not shown). Thisalready occupied in pro-B cells purified from RAG2/2
mice. The intensity of the NF-kB footprint did not in- is also consistent with the idea that BSAP binding might
prevent binding of PU.1 to the 39k enhancer in pro-Bcrease when pre-B cells from RAG2/2, m transgenic mice
were analyzed. In addition, we failed to detect the foot- cells. In addition, we detected a complex in progenitor
T cells that comigrated with the B cell–specific BSAPprint over the kE2 site that was apparent in transformed
cells. As noted above, deletion of the intronic enhancer complex but still bound to a probe with a mutant BSAP
site. The levels of this complex were increased wheninhibits k rearrangement (Takeda et al., 1993; Xu et al.,
1996; Zou et al., 1993). We therefore suggest that NF- evaluated with a mutant PU.1 site–containing probe.
It is possible that progenitor B cells also express thiskB binding might be necessary but not sufficient for
efficient activation of the k locus. It is possible that the complex (Figure 6B).
A recent report implicated the 39k enhancer and itslow levels of germline k transcription and V-to-Jk gene
rearrangement observed in pro-B cells are dependent PU.1 site in the regulation of k gene rearrangement (Hi-
ramatsu et al., 1995). These workers found that mutationon the binding of NF-kB to the intronic enhancer. This
is consistent with the decrease but not elimination of k of the PU.1 site in a transgenic rearrangement reporter
construct containing both the intronic and 39k en-locus activation in the setting of targeted deletion of the
39k enhancer (Gorman et al., 1996). While the identity hancers resulted in precocious V-to-Jk rearrangement
during B cell development and activation of k re-of the proteins responsible for the NF-kB site footprint
in pro- and pre-B cells remains uncertain, we detected arrangement in thymocytes. As noted above, using a
39k enhancer probe containing a mutant PU.1 site, wechanges in the relative amounts of p65- and c-rel-con-
observed a striking increase in the levels of a DNA–taining complexes in nuclear extracts from these cells,
protein complexthat comigrates with the BSAP complexleading us to suggest that changes in the proteins bound
in both thymocyte and pro-B cell nuclear extract (com-to this site might contribute to k locus activation (Fig-
pare Figure 6B, left, lanes 1 and 16, with Figure 6A, lanesure 4). Mutant mice lacking p50, RelB, and c-rel, how-
1 and 16). While we have not yet identified the proteinever, rearrange and expressnormal levels of Igk, arguing
component of this complex, it is possible that it is re-against the specific requirement for these rel family
sponsible for enhancer activation in the setting of PU.1members in activation of the k locus.
mutation. We have not, however, observed any in vivo
footprint in T cell lines or primary thymocytes at the 39k
A Model for the Developmental Regulation enhancer (data not shown), which leads us to suggest
of the k Locus that this factor might bind the enhancer in a manner
Although in vivo footprinting failed to detect a change dissimilar to BSAP.
in occupied sites within the intronic enhancer during the Based on our data, we propose the following specula-
pro- to pre-B cell transition, it did reveal a striking tive model of k locus activation during B cell develop-
ment (Figure7). Activation of p50/p65 NF-kB early duringchange in the 39k enhancer (Figure 5). These changes
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cells with an antibody to the B cell marker B220 (PE-conjugated
anti-B220; Pharmingen) and by light scatter criteria.
Cell Culture
Cell lines were grown at 378C, 5% CO2 in RPMI-1640 (GIBCO BRL)
supplemented with 10% fetal calf serum, penicillin–streptomycin,
and 50 mM b-mercaptoethanol. Some cell lines were treated with
LPS (Difco) in vitro (10 mg/ml for 18–24 hr) or with PMA (Sigma; 10
ng/ml for 4 hr) prior to in vitro footprinting. The following cell lines
were used: 63-12, a transformed RAG2-deficient pro-B cell line
(Shinkai et al., 1992); 220-8, a transformed pro-B cell line (Schlissel
and Baltimore, 1989); and 2017, a transformedpre-T cell line (Spolski
et al., 1988).
In Vivo DMS Footprinting
DNA was prepared for footprinting as described (Ausubel et al.,Figure 7. A Model for k Locus Activation
1987) with the following modifications. Several million cells were
The model shows changes in the factors bound to the 39k enhancer
pelleted and resuspended in 1 ml of CS/PBS and placed in 50 ml
that might be responsible for the increases in germline k transcrip- conical tubes at 378C. We added 10 ml of 10% DMS (diluted in
tion and V-to-Jk rearrangement observed in pre-B cells. The intronic
EtOH) to the cells for 1 min. Ice-cold CS/PBS (50 ml) was added
enhancer NF-kB site is occupied in both pro- and pre-B cells, but the
immediately, cells were pelleted, and DNA was purified. Piperidine
nature of the complex on that sight might differ with development.
treatment of 30–100 mg of DNA for both in vitro and in vivo DMS-
treated samples was as described (Ausubel et al., 1987).
We subjected 1 mg of each piperidine-treated DNA sample to
LM–PCR (Mueller and Wold, 1989). Primer extension was performedB cell development, possibly in conjunction with other
with the k locus–specific primers listed below, with an extensionenhancer-binding factors, results in basal levels of
cycle of 958C for 5 min, 588C for 30 min, and 768C for 10 min. Double-germline k locus transcription and V-to-Jk gene re-
stranded linker (Mueller and Wold, 1989; 59-GCGGTGACCCGGGAG
arrangement. In pro-B cells, high levels of BSAP bound ATCTGAATTC, top; 59-GAATTCAGATC, bottom) was ligated to the
to its site in the 39k enhancer prevent PU.1 binding. extension product overnight at 168C with T4 DNA ligase (New En-
Once a cell makes heavy chain protein, a pre-BCR- gland Biolabs) as described (Mueller and Wold, 1989). Amplification
of ligation products was performed with the extension primer anddependent signaling pathway results in a decrease in
the linker primer (Garrity and Wold, 1992; Mueller and Wold, 1989).BSAP binding. PU.1 (and possibly a CRE-binding pro-
Samples were heated in the absence of Vent polymerase (New En-tein) can then bind to their target sites, activating the
gland Biolabs) to 808C for 5 min, polymerase was added, and the
39k enhancer and resulting in the observed increase samples were subjected to PCR as follows: 958C for 3 min, 588C for
in germline k transcription and rearrangement in pre-B 2 min, and 768C for 3 min for 1 cycle, followed by 958C for 1 min,
cells. 608C for 2 min, and 768C for 3 min for 18 cycles. Radioactively 59
end–labeled primers (see below) were added for 4 final cycles of
958C for 1 min, 608C for 2 min, 768C for 10 min. After PCR, DNA wasExperimental Procedures
precipitated, resuspended in loading dye (Sequenase; United States
Biochemicals), heated to 908C, and run on a standard 6% polyacryl-Cell Purification
amide–urea sequencing gel. Gels were dried and exposed to X-rayDNA for in vivo footprinting, RNA for reverse transcription–PCR
film (Kodak) or phosphorimager screens (Molecular Dynamics) foranalysis, and nuclear extracts for gel mobility shift assays were
16–24 hr before data analysis.obtained from cells purified from RAG1-deficient, RAG1-deficient
Footprinting primers were as follows. For the k intronic enhancer:heavy chain transgenic (Spanopoulou et al., 1994), and wild-type
primer extension for top strand, MD3, 59-TGTATGGCTTCCTTTGGT(Balb/c) mice as described previously (Stanhope-Baker et al., 1996).
GTAGCCA; primer extension for bottom strand, MD3R, 59-TGTGTTTBone marrow cells were recovered from femurs, tibia, and humeri
GACCCTTCCCTGCCAAAG; locus-specific, 32P-labeled, for topby flushing bones with 10% calf serum, 13 PBS, 0.01% sodium
strand, MD7, 59-GTATTTGGGTGTCCAGAAATATTCTGAGC; locus-azide (CS/PBS). Splenocytes and thymocytes were obtained by dis-
specific, 32P-labeled, for bottom strand, MD7R2, 59-CCTTTAAAsection and manual disruption of the organ. The cell suspension
ACTCTTGAACTACTTTAGAGTC. For the 39k enhancer: primerwas passed through nylon mesh, layered on Ficoll, and centrifuged
extension for top strand, 3D, 59-CAAGTTGAGTTTTGACTGTGC, orat 208C at 400 3 g for 15 min. Live cells at the “buffy coat” were
3D2, 59-CCATGAAACATCTTTTCCAC; primer extension for bottomaspirated by pipette, leaving dead cells and red blood cells behind.
strand, 3U2, 59-TCAGTATAGCACAGAGTACC; locus-specific, 32P-From this point, cells were kept at 48C or on ice. Live cells were then
labeled, for top strand, 3D (with 3D2, as above); 3R (with 3D),washed in several volumes of CS/PBS, pelleted, and resuspended in
59-ATCATTTCATCCCAGTGCTG; locus-specific, 32P-labeled, forCS/PBS with a biotinylated anti-CD19 antibody (Krop et al., 1996)
bottom strand, 3U, 59-GATTTTCATGGTGACTGGC.for 15 min on ice. Cells were washed once in 2 ml per 107 cells
of CS/PBS, once in an equal volume of 0.5% BSA, 13 PBS, and
resuspended in 90 ml per 107 cells of 0.5% BSA, 13 PBS. We added Gel Mobility Shift Assays
The two complementary strands of each oligonucleotide probe (see10 ml per 107 cells of streptavidin-coated paramagnetic beads (Mill-
tenyi Biotech) and incubated the mixture at 48C for 15 min. Cell below) were annealed in TE (10 mM Tris [pH 7.4], 1 mM EDTA) with
50 mM NaCl at a concentration of 100 ng/ml by heating to 958C forsuspensions were passed through nylon mesh onto a MiniMACS
(Milltenyi Biotech) column attached to a magnet at 48C. Columns 5 min and 708C for 30 min and cooling at approximately 18C per
minute to 228C. PCR was used to generate labeled mobility shiftwere washed twicewith 0.5% BSA, 13PBS, andcells were collected
from the flowthrough and designated as depleted. These fractions probes BSAP–PU.1/pip and its mutant versions from genomic DNA
templates, with 39 enhancer–specific primers 39k BSAP (top) andtypically contained less than 10% CD191 cells. The column was
removed from the magnet, and cells designated enriched where PU.1/pip (bottom; longer oligonucleotide) or appropriate mutants
using cycles of 948C for 1 min, 608C for 1 min, and 728C for 1.5 minwashed free in several milliliters of 0.5% BSA, 13 PBS. A small
aliquot of cells was removed and restained with anti-CD19 antibody for 30–32 cycles. PCR products were run on 10% polyacrylamide
gels in 0.53 TBE, and double-stranded products were excised,and streptavidin–Quantum red (Sigma) to monitor the purity of cells
by flow cytometry. Enriched fractions were .90% CD191. Purity was eluted in 400 mM ammonium acetate, 10 mM magnesium acetate
overnight at 378C, precipitated, and quantified. We 59 end–labeledalso confirmed by simultaneous staining of independent aliquots of
Regulation of Germline k Locus Transcription
141
100 ng of each probe with [g-32P]ATP using T4 polynucleotide kinase Science Foundation predoctoral fellowship and training grant NIH
5T32 AI07247; and M. S. S. acknowledges the support of a Culpeper(New England Biolabs) for 30 min at 378C. Probes were separated
from excess radioactive nucleotides by passage over a nucleotide Foundation Scholarship and a Cancer Research Institute Investiga-
tor Award.removal column (Qiagen) with elution of the probe in 50 mM NaCl,
10 mM Tris (pH 7.4), 1 mM EDTA or by polyacrylamide gel electro-
phoresis as described above. Probes (at approximately 1 ng/ml) Received November 8, 1996; revised December 23, 1996.
typically labeled to 1 3 108 cpm/mg or greater.
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